

12-18-01  
BEST AVAILABLE COPY

A/Box/sec

12/18/01  
JC962 U.S. PTO

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b>  (Only for new nonprovisional applications under 37 CFR 1.53(b))	Attorney Docket No.	C1037/7025/HCL/MAT
	First Named Inventor or Application Identifier	
	Robert L. Bratzler	
	Express Mail Label No.	EL844533552US
	Date of Deposit	December 14, 2001

JC962 U.S. PTO  
10/017995

12/18/01

APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents</i>	ADDRESS TO: Box Patent Application Commissioner for Patents Washington, DC 20231
<p>1. <input type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</p> <p>2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.</p> <p>3. <input checked="" type="checkbox"/> Specification - Total pages 69 60 - pages description 1 - pages abstract 8 - pages claims 74- Total claims</p> <p>4. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) 1 - Total sheets <input checked="" type="checkbox"/> Informal <input type="checkbox"/> Formal 1 - Total drawings</p> <p>5. <input type="checkbox"/> Oath or Declaration - Total pages a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) [Note Box 6 below] i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>6. <input type="checkbox"/> Incorporation by Reference (usable if Box 5b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. See 19.</p> <p>7. <input checked="" type="checkbox"/> Application Data Sheet, See 37 CFR 1.76</p>	<p>8. <input type="checkbox"/> CD-ROM or CD-R, in duplicate, large table or Computer Program (Appendix)</p> <p>9. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input checked="" type="checkbox"/> Computer Readable Form (CRF) b. <input checked="" type="checkbox"/> Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input checked="" type="checkbox"/> paper (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above copies</p> <p><b>ACCOMPANYING APPLICATION PARTS</b></p> <p>10. <input type="checkbox"/> Assignment Papers/cover sheet &amp; documents(s)</p> <p>11. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an assignee) <input type="checkbox"/> Power of Attorney</p> <p>12. <input type="checkbox"/> English Translation of Document (if applicable)</p> <p>13. <input type="checkbox"/> Information Disclosure Statement/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>14. <input type="checkbox"/> Preliminary Amendment</p> <p>15. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)</p> <p>16. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)</p> <p>17. <input type="checkbox"/> Request and Certification Under 35 U.S.C. §122(b)(2)(B)(ii)</p> <p>18. <input checked="" type="checkbox"/> Other: This application claims priority under 35 U.S.C. §119(e) from U.S. Provisional Patent Application Serial No. 60/255,534 filed on December 14, 2000, entitled INHIBITION OF ANGIOGENESIS BY NUCLEIC ACIDS. The entire contents of the provisional application are hereby expressly incorporated by reference.</p>

19. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the body of the application, or a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_, filed on \_\_\_\_\_, entitled \_\_\_\_\_ and now \_\_\_\_\_.

☐ Cancel in this application claims \_\_\_\_\_ before calculating the filing fee.

☐ Amend the specification by inserting before the first line of the specification on page 1, after the title, the following:

--This application is a ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_, filed on \_\_\_\_\_, entitled \_\_\_\_\_ and now \_\_\_\_\_.--

Prior application information: Examiner \_\_\_\_\_ Group Art Unit: \_\_\_\_\_

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

#### 20. CORRESPONDENCE ADDRESS

Correspondence address below

CUSTOMER NUMBER:



23628

OR

AGENT'S NAME	Maria A. Trevisan				
FIRM NAME	Wolf, Greenfield & Sacks, P.C.				
ADDRESS	600 Atlantic Avenue				
CITY	Boston	STATE	MA	ZIP	02210
COUNTRY	USA	TELEPHONE	(617) 720-3500	FAX	(617) 720-2441

  

20. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	
NAME	Maria A. Trevisan, Reg. No. 48,207
SIGNATURE	
DATE	December 14, 2001